SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'CJT'


List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_A_STIA201_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 6 LYS A 213
VAL A 246
MET A 265
ARG A 310
 CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.9A)
TPO  A 345 ( 4.9A)
 1.09A 1iepA-6f3dA:
23.3		 1iepA-6f3dA:
13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_B_STIB202_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 7 LYS A 213
VAL A 246
MET A 265
LEU A 318
 CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.9A)
CJT  A 502 (-4.7A)
 0.81A 1iepB-6f3dA:
23.5		 1iepB-6f3dA:
13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_B_STIB202_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 7 VAL A 246
MET A 265
ARG A 310
LEU A 318
 None
CJT  A 502 (-4.9A)
TPO  A 345 ( 4.9A)
CJT  A 502 (-4.7A)
 0.87A 1iepB-6f3dA:
23.5		 1iepB-6f3dA:
13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1TT6_A_DESA129_1
(TRANSTHYRETIN)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 4 LYS A 213
LEU A 215
LEU A 258
SER A 253
 CJT  A 502 (-3.0A)
None
None
None
 1.14A 1tt6A-6f3dA:
undetectable		 1tt6A-6f3dA:
16.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2EVA_A_ADNA498_1
(TAK1 KINASE - TAB1
CHIMERA FUSION
PROTEIN)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 11 GLY A 193
VAL A 200
ALA A 211
TYR A 264
SER A 269
LEU A 318
 CJT  A 502 ( 3.9A)
CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 0.48A 2evaA-6f3dA:
24.8		 2evaA-6f3dA:
14.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WGJ_A_VGHA2346_1
(HEPATOCYTE GROWTH
FACTOR RECEPTOR)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 12 GLY A 193
VAL A 200
ALA A 211
TYR A 264
MET A 265
GLY A 268
ASP A 329
 CJT  A 502 ( 3.9A)
CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-4.5A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 ( 4.0A)
 0.80A 2wgjA-6f3dA:
24.6		 2wgjA-6f3dA:
15.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XP2_A_VGHA9000_1
(TYROSINE-PROTEIN
KINASE RECEPTOR)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 9 VAL A 200
ALA A 211
MET A 265
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.51A 2xp2A-6f3dA:
24.5		 2xp2A-6f3dA:
13.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6O_A_1N1A1892_1
(EPHRIN TYPE-A
RECEPTOR 4)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 12 ALA A 211
GLU A 233
MET A 237
TYR A 264
GLY A 268
LEU A 318
SER A 328
 CJT  A 502 (-3.4A)
CJT  A 502 (-3.9A)
None
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.3A)
 1.15A 2y6oA-6f3dA:
24.8		 2y6oA-6f3dA:
16.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7J_C_B49C1294_1
(PHOSPHORYLASE B
KINASE GAMMA
CATALYTIC CHAIN,
TESTIS/LIVER ISOFORM)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 10 VAL A 200
ALA A 211
MET A 265
GLY A 268
ASP A 272
LEU A 318
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-3.3A)
CJT  A 502 (-4.7A)
 0.57A 2y7jC-6f3dA:
24.3		 2y7jC-6f3dA:
10.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7J_D_B49D1294_1
(PHOSPHORYLASE B
KINASE GAMMA
CATALYTIC CHAIN,
TESTIS/LIVER ISOFORM)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 10 VAL A 200
ALA A 211
MET A 265
GLY A 268
ASP A 272
LEU A 318
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-3.3A)
CJT  A 502 (-4.7A)
 0.45A 2y7jD-6f3dA:
24.7		 2y7jD-6f3dA:
10.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3EYG_A_MI1A1_1
(TYROSINE-PROTEIN
KINASE)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		8 / 12 GLY A 193
GLY A 195
GLY A 198
VAL A 200
ALA A 211
LYS A 213
SER A 269
LEU A 318
 CJT  A 502 ( 3.9A)
None
None
CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 0.67A 3eygA-6f3dA:
25.6		 3eygA-6f3dA:
14.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3FUP_A_MI1A1_1
(TYROSINE-PROTEIN
KINASE JAK2)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		9 / 12 GLY A 193
GLY A 195
GLY A 198
VAL A 200
ALA A 211
LYS A 213
TYR A 264
SER A 269
LEU A 318
 CJT  A 502 ( 3.9A)
None
None
CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 0.79A 3fupA-6f3dA:
24.8		 3fupA-6f3dA:
12.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3FUP_B_MI1B1_1
(TYROSINE-PROTEIN
KINASE JAK2)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 12 GLY A 193
GLY A 195
VAL A 200
ALA A 211
LYS A 213
TYR A 264
LEU A 318
 CJT  A 502 ( 3.9A)
None
CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.5A)
CJT  A 502 (-4.7A)
 0.47A 3fupB-6f3dA:
24.8		 3fupB-6f3dA:
12.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IK3_A_0LIA1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		5 / 12 ALA A 211
LEU A 245
VAL A 246
HIS A 309
LEU A 318
 CJT  A 502 (-3.4A)
None
None
None
CJT  A 502 (-4.7A)
 0.55A 3ik3A-6f3dA:
23.2		 3ik3A-6f3dA:
13.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IK3_B_0LIB2_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		5 / 12 ALA A 211
LEU A 245
VAL A 246
HIS A 309
LEU A 318
 CJT  A 502 (-3.4A)
None
None
None
CJT  A 502 (-4.7A)
 0.62A 3ik3B-6f3dA:
23.0		 3ik3B-6f3dA:
13.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LXN_A_MI1A1_1
(NON-RECEPTOR
TYROSINE-PROTEIN
KINASE TYK2)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		8 / 12 GLY A 193
GLY A 195
VAL A 200
ALA A 211
LYS A 213
TYR A 264
SER A 269
LEU A 318
 CJT  A 502 ( 3.9A)
None
CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 0.56A 3lxnA-6f3dA:
24.8		 3lxnA-6f3dA:
11.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MIY_A_B49A1_1
(TYROSINE-PROTEIN
KINASE ITK/TSK)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 11 ALA A 211
VAL A 246
MET A 265
GLY A 268
LEU A 318
SER A 328
 CJT  A 502 (-3.4A)
None
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.3A)
 0.73A 3miyA-6f3dA:
25.4		 3miyA-6f3dA:
13.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MIY_B_B49B2_1
(TYROSINE-PROTEIN
KINASE ITK/TSK)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		5 / 9 ALA A 211
MET A 265
GLY A 268
LEU A 318
SER A 328
 CJT  A 502 (-3.4A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.3A)
 0.70A 3miyB-6f3dA:
25.4		 3miyB-6f3dA:
13.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MS9_A_STIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 6 LYS A 213
VAL A 246
MET A 265
ARG A 310
 CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.9A)
TPO  A 345 ( 4.9A)
 1.02A 3ms9A-6f3dA:
23.3		 3ms9A-6f3dA:
13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MS9_A_STIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 6 VAL A 236
VAL A 246
MET A 265
ARG A 310
 None
None
CJT  A 502 (-4.9A)
TPO  A 345 ( 4.9A)
 1.01A 3ms9A-6f3dA:
23.3		 3ms9A-6f3dA:
13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_A_STIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 6 LYS A 213
VAL A 246
MET A 265
ARG A 310
 CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.9A)
TPO  A 345 ( 4.9A)
 1.06A 3mssA-6f3dA:
23.4		 3mssA-6f3dA:
13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_A_STIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 6 VAL A 236
VAL A 246
MET A 265
ARG A 310
 None
None
CJT  A 502 (-4.9A)
TPO  A 345 ( 4.9A)
 1.03A 3mssA-6f3dA:
23.4		 3mssA-6f3dA:
13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_C_STIC1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 6 LYS A 213
VAL A 246
MET A 265
ARG A 310
 CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.9A)
TPO  A 345 ( 4.9A)
 1.12A 3mssC-6f3dA:
23.2		 3mssC-6f3dA:
13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_C_STIC1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 6 VAL A 236
VAL A 246
MET A 265
ARG A 310
 None
None
CJT  A 502 (-4.9A)
TPO  A 345 ( 4.9A)
 1.08A 3mssC-6f3dA:
23.2		 3mssC-6f3dA:
13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_D_STID1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 6 VAL A 200
LYS A 213
VAL A 246
MET A 265
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.9A)
 0.73A 3mssD-6f3dA:
23.5		 3mssD-6f3dA:
13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OCT_A_1N1A663_1
(TYROSINE-PROTEIN
KINASE BTK)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 12 VAL A 200
ALA A 211
LYS A 213
VAL A 246
TYR A 264
GLY A 268
LEU A 318
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 0.69A 3octA-6f3dA:
23.8		 3octA-6f3dA:
13.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OXZ_A_0LIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 12 ALA A 211
LEU A 245
VAL A 246
GLY A 268
HIS A 309
ASP A 329
 CJT  A 502 (-3.4A)
None
None
CJT  A 502 ( 4.3A)
None
CJT  A 502 ( 4.0A)
 0.90A 3oxzA-6f3dA:
23.5		 3oxzA-6f3dA:
13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3SXR_A_1N1A1_1
(CYTOPLASMIC
TYROSINE-PROTEIN
KINASE BMX)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 12 VAL A 200
ALA A 211
VAL A 246
TYR A 264
GLY A 268
LEU A 318
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
None
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 0.43A 3sxrA-6f3dA:
25.3		 3sxrA-6f3dA:
17.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3SXR_B_1N1B2_1
(CYTOPLASMIC
TYROSINE-PROTEIN
KINASE BMX)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 12 VAL A 200
ALA A 211
VAL A 246
TYR A 264
GLY A 268
LEU A 318
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
None
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 0.44A 3sxrB-6f3dA:
24.7		 3sxrB-6f3dA:
17.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3SXR_B_1N1B2_1
(CYTOPLASMIC
TYROSINE-PROTEIN
KINASE BMX)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 12 VAL A 200
ALA A 211
VAL A 246
TYR A 264
GLY A 268
SER A 328
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
None
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 ( 4.3A)
 0.49A 3sxrB-6f3dA:
24.7		 3sxrB-6f3dA:
17.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UG2_A_IREA1_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 12 ALA A 211
LYS A 213
LEU A 260
MET A 265
GLY A 268
ASP A 272
LEU A 318
 CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-3.3A)
CJT  A 502 (-4.7A)
 0.60A 3ug2A-6f3dA:
24.2		 3ug2A-6f3dA:
9.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UG2_A_IREA1_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 12 VAL A 200
ALA A 211
LYS A 213
LEU A 260
MET A 265
GLY A 268
LEU A 318
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 0.39A 3ug2A-6f3dA:
24.2		 3ug2A-6f3dA:
9.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WZD_A_LEVA1201_2
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 5 LYS A 213
VAL A 246
LEU A 318
ASP A 329
 CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 1.01A 3wzdA-6f3dA:
23.3		 3wzdA-6f3dA:
15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AF0_A_MOAA1526_1
(INOSINE-5'-MONOPHOSP
HATE DEHYDROGENASE)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 8 ASP A 272
ARG A 273
MET A 265
GLY A 193
 CJT  A 502 (-3.3A)
None
CJT  A 502 (-4.9A)
CJT  A 502 ( 3.9A)
 1.02A 4af0A-6f3dA:
undetectable		 4af0A-6f3dA:
10.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ANQ_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 9 VAL A 200
ALA A 211
MET A 265
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.59A 4anqA-6f3dA:
24.1		 4anqA-6f3dA:
13.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ANS_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 9 VAL A 200
ALA A 211
MET A 265
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.63A 4ansA-6f3dA:
24.0		 4ansA-6f3dA:
13.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_2
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		5 / 5 VAL A 200
ILE A 327
TYR A 264
MET A 265
ILE A 317
 CJT  A 502 ( 4.8A)
None
CJT  A 502 (-4.5A)
CJT  A 502 (-4.9A)
None
 1.10A 4c8bA-6f3dA:
8.9		 4c8bA-6f3dA:
12.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_B_0LIB1000_2
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		3 / 3 TYR A 264
MET A 265
ILE A 317
 CJT  A 502 (-4.5A)
CJT  A 502 (-4.9A)
None
 0.85A 4c8bB-6f3dA:
25.0		 4c8bB-6f3dA:
12.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_B_0LIB1000_2
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		3 / 3 TYR A 264
MET A 265
ILE A 327
 CJT  A 502 (-4.5A)
CJT  A 502 (-4.9A)
None
 0.46A 4c8bB-6f3dA:
25.0		 4c8bB-6f3dA:
12.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CKJ_A_ADNA2014_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 10 GLY A 193
GLY A 195
VAL A 200
ALA A 211
TYR A 264
SER A 269
LEU A 318
 CJT  A 502 ( 3.9A)
None
CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 0.77A 4ckjA-6f3dA:
27.1		 4ckjA-6f3dA:
14.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4D7B_A_TCWA1126_1
(TRANSTHYRETIN)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 6 LYS A 213
LEU A 215
LEU A 258
SER A 253
 CJT  A 502 (-3.0A)
None
None
None
 1.13A 4d7bB-6f3dA:
undetectable		 4d7bB-6f3dA:
16.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4I22_A_IREA9001_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		8 / 12 GLY A 193
VAL A 200
ALA A 211
LYS A 213
LEU A 260
GLY A 268
ASP A 272
LEU A 318
 CJT  A 502 ( 3.9A)
CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
None
CJT  A 502 ( 4.3A)
CJT  A 502 (-3.3A)
CJT  A 502 (-4.7A)
 0.49A 4i22A-6f3dA:
22.4		 4i22A-6f3dA:
9.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXX_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 12 VAL A 200
ALA A 211
VAL A 246
TYR A 264
MET A 265
GLY A 268
LEU A 318
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
None
CJT  A 502 (-4.5A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 0.50A 4mxxB-6f3dA:
23.6		 4mxxB-6f3dA:
13.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXY_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		8 / 12 VAL A 200
ALA A 211
GLU A 233
VAL A 246
TYR A 264
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.9A)
None
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.66A 4mxyA-6f3dA:
25.7		 4mxyA-6f3dA:
13.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXY_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		8 / 12 VAL A 200
ALA A 211
LYS A 213
VAL A 246
TYR A 264
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.62A 4mxyA-6f3dA:
25.7		 4mxyA-6f3dA:
13.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXY_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		9 / 12 VAL A 200
ALA A 211
LYS A 213
GLU A 233
VAL A 246
TYR A 264
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 (-3.9A)
None
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.79A 4mxyB-6f3dA:
25.6		 4mxyB-6f3dA:
13.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXZ_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		8 / 12 VAL A 200
ALA A 211
GLU A 233
VAL A 246
TYR A 264
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.9A)
None
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.66A 4mxzA-6f3dA:
25.7		 4mxzA-6f3dA:
13.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXZ_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		8 / 12 VAL A 200
ALA A 211
LYS A 213
VAL A 246
TYR A 264
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.62A 4mxzA-6f3dA:
25.7		 4mxzA-6f3dA:
13.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXZ_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		9 / 12 VAL A 200
ALA A 211
LYS A 213
GLU A 233
VAL A 246
TYR A 264
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 (-3.9A)
None
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.79A 4mxzB-6f3dA:
25.6		 4mxzB-6f3dA:
13.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TWP_A_AXIA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		8 / 12 VAL A 200
ALA A 211
LYS A 213
MET A 265
GLY A 268
ASN A 316
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
None
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.78A 4twpA-6f3dA:
25.3		 4twpA-6f3dA:
15.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TWP_B_AXIB601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		8 / 12 VAL A 200
ALA A 211
LYS A 213
MET A 265
GLY A 268
ASN A 316
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
None
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.85A 4twpB-6f3dA:
25.7		 4twpB-6f3dA:
15.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		9 / 11 GLY A 195
VAL A 200
ALA A 211
TYR A 264
MET A 265
GLY A 268
ASN A 316
LEU A 318
ASP A 329
 None
CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-4.5A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
None
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.48A 4u5jA-6f3dA:
26.1		 4u5jA-6f3dA:
13.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_B_RXTB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 9 VAL A 200
ALA A 211
TYR A 264
MET A 265
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-4.5A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.69A 4u5jB-6f3dA:
25.3		 4u5jB-6f3dA:
13.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4UXQ_A_0LIA1752_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 7 VAL A 200
LYS A 213
ARG A 310
ILE A 327
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.0A)
TPO  A 345 ( 4.9A)
None
 0.87A 4uxqA-6f3dA:
24.0		 4uxqA-6f3dA:
14.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V01_A_0LIA1776_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 9 VAL A 200
LYS A 213
TYR A 264
ARG A 310
LEU A 318
ILE A 327
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.5A)
TPO  A 345 ( 4.9A)
CJT  A 502 (-4.7A)
None
 0.69A 4v01A-6f3dA:
22.7		 4v01A-6f3dA:
13.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V01_B_0LIB1770_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 9 VAL A 200
LYS A 213
TYR A 264
ARG A 310
LEU A 318
ILE A 327
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.5A)
TPO  A 345 ( 4.9A)
CJT  A 502 (-4.7A)
None
 0.95A 4v01B-6f3dA:
23.3		 4v01B-6f3dA:
13.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V04_A_0LIA1772_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		5 / 8 LYS A 213
TYR A 264
ARG A 310
LEU A 318
ILE A 327
 CJT  A 502 (-3.0A)
CJT  A 502 (-4.5A)
TPO  A 345 ( 4.9A)
CJT  A 502 (-4.7A)
None
 1.05A 4v04A-6f3dA:
23.0		 4v04A-6f3dA:
13.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V04_B_0LIB1771_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 10 VAL A 200
LYS A 213
TYR A 264
ARG A 310
LEU A 318
ILE A 327
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.5A)
TPO  A 345 ( 4.9A)
CJT  A 502 (-4.7A)
None
 1.03A 4v04B-6f3dA:
23.3		 4v04B-6f3dA:
13.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WA9_A_AXIA9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 11 ALA A 211
LYS A 213
MET A 265
GLY A 268
ASN A 316
LEU A 318
 CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
None
CJT  A 502 (-4.7A)
 0.95A 4wa9A-6f3dA:
22.0		 4wa9A-6f3dA:
11.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XLI_A_1N1A601_1
(NON-SPECIFIC
PROTEIN-TYROSINE
KINASE)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		8 / 12 ALA A 211
GLU A 233
MET A 237
VAL A 246
TYR A 264
MET A 265
GLY A 268
LEU A 318
 CJT  A 502 (-3.4A)
CJT  A 502 (-3.9A)
None
None
CJT  A 502 (-4.5A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 1.06A 4xliA-6f3dA:
26.4		 4xliA-6f3dA:
16.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XLI_A_1N1A601_1
(NON-SPECIFIC
PROTEIN-TYROSINE
KINASE)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 12 ALA A 211
LYS A 213
VAL A 246
TYR A 264
MET A 265
GLY A 268
LEU A 318
 CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
None
CJT  A 502 (-4.5A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 0.58A 4xliA-6f3dA:
26.4		 4xliA-6f3dA:
16.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5AAA_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 9 VAL A 200
ALA A 211
MET A 265
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.53A 5aaaA-6f3dA:
24.5		 5aaaA-6f3dA:
13.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5AAB_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 10 VAL A 200
ALA A 211
LYS A 213
MET A 265
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.58A 5aabA-6f3dA:
24.3		 5aabA-6f3dA:
13.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5AAC_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 10 VAL A 200
ALA A 211
LYS A 213
MET A 265
GLY A 268
LEU A 318
ASP A 329
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.70A 5aacA-6f3dA:
24.0		 5aacA-6f3dA:
13.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BOJ_B_4TXB201_1
(TRANSTHYRETIN)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		4 / 7 LYS A 213
LEU A 215
LEU A 258
SER A 253
 CJT  A 502 (-3.0A)
None
None
None
 1.02A 5bojB-6f3dA:
undetectable		 5bojB-6f3dA:
16.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5I9X_A_DB8A1001_1
(EPHRIN TYPE-A
RECEPTOR 2)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 12 ALA A 211
LYS A 213
TYR A 264
GLY A 268
LEU A 318
SER A 328
 CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.3A)
 0.43A 5i9xA-6f3dA:
25.1		 5i9xA-6f3dA:
13.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MO4_A_NILA601_2
(TYROSINE-PROTEIN
KINASE ABL1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		5 / 12 ALA A 211
LEU A 245
VAL A 246
HIS A 309
LEU A 318
 CJT  A 502 (-3.4A)
None
None
None
CJT  A 502 (-4.7A)
 0.55A 5mo4A-6f3dA:
20.0		 5mo4A-6f3dA:
10.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VC3_A_DB8A601_1
(WEE1-LIKE PROTEIN
KINASE)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 12 GLY A 193
ALA A 211
GLU A 233
TYR A 264
GLY A 268
ASP A 272
ASP A 329
 CJT  A 502 ( 3.9A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.9A)
CJT  A 502 (-4.5A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-3.3A)
CJT  A 502 ( 4.0A)
 0.89A 5vc3A-6f3dA:
19.0		 5vc3A-6f3dA:
14.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5YU9_B_1E8B1101_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		6 / 12 GLY A 193
VAL A 200
ALA A 211
LEU A 260
ASP A 272
LEU A 318
 CJT  A 502 ( 3.9A)
CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
None
CJT  A 502 (-3.3A)
CJT  A 502 (-4.7A)
 0.60A 5yu9B-6f3dA:
22.4		 5yu9B-6f3dA:
26.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5YU9_C_1E8C1101_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		5 / 12 VAL A 200
ALA A 211
LEU A 260
GLY A 268
ASP A 272
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
None
CJT  A 502 ( 4.3A)
CJT  A 502 (-3.3A)
 0.59A 5yu9C-6f3dA:
22.0		 5yu9C-6f3dA:
26.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5ZV2_A_LEVA801_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		3 / 3 LYS A 213
LEU A 318
ASP A 329
 CJT  A 502 (-3.0A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.0A)
 0.73A 5zv2A-6f3dA:
23.1		 5zv2A-6f3dA:
34.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BSD_A_1N1A901_0
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 12 VAL A 200
ALA A 211
LYS A 213
TYR A 264
MET A 265
GLY A 268
LEU A 318
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.0A)
CJT  A 502 (-4.5A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
 0.43A 6bsdA-6f3dA:
22.5		 6bsdA-6f3dA:
17.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6FNM_A_1N1A1001_1
(-)		 6f3d INTERLEUKIN-1
RECEPTOR-ASSOCIATED
KINASE 4
(Homo
sapiens) 		7 / 12 VAL A 200
ALA A 211
GLU A 233
MET A 265
GLY A 268
LEU A 318
SER A 328
 CJT  A 502 ( 4.8A)
CJT  A 502 (-3.4A)
CJT  A 502 (-3.9A)
CJT  A 502 (-4.9A)
CJT  A 502 ( 4.3A)
CJT  A 502 (-4.7A)
CJT  A 502 ( 4.3A)
 0.84A 6fnmA-6f3dA:
25.0		 6fnmA-6f3dA:
13.24